issue contents
February 2018 issue

Cover illustration: Over the past few years, metformin hydrochloride (1,1-dimethylbiguanide hydrochloride) has been the most commonly used drug for the first-line treatment of type 2 diabetes. On the other hand, acetylsalicylic acid, which is one of the most used general pain-relieving drugs, has been associated with copper in the form of copper acetylsalicylate to treat rheumatoid arthritis and thromboembolic diseases. The synthesis and crystal structure of a new CuII complex that contains both active pharmaceutical ingredients chelating to the central metal cation, namely neutral metformin and the salicylate dianion, is reported. The hydrous complex (metformin-2N,N')(salicylato-
2O,O')copper(II) trihydrate [systematic name: (1,1-dimethylbiguanide-
2N2,N4)(2-oxidobenzoato-
2O,O')copper(II) trihydrate] was synthesized electrolytically from an ethanolic solution of metformin hydrochloride, acetylsalicylic acid, Pepto-Bismol and a copper sacrificial anode. Diffraction data were collected at 0.56 Å resolution, allowing the accurate determination of H-atom positions in the neutral metformin ligand. See: Gutiérrez Ojeda, Salazar Kuri, Bernès & Pérez-Benítez [IUCrData (2017). 3, x180180].
inorganic compounds












metal-organic compounds



organic compounds












































